業績

Nobuya Abe and Yuichiro Fujieda.

Chronic active Epstein-Barr virus infection.

Blood. 2020; in press.

IF 17.543

Nakazawa D and Ishizu A.

Immunothrombosis in Severe COVID-19.

EBioMedicine. in press

IF 6.490

OgataY, Fujieda Y, Sugawara M, Sato T, Ohnishi N, Kono M, Kato M, Oku K, Amengual O, Atsumi T Morbidity and mortality in antiphospholipid syndrome based on cluster

analysis: a 10-year longitudinal cohort study Rheumatology

IF:5.245

Fujieda Y, Amengual O

New insights into the mechanism and treatment of arterial thrombosis in antiphospholipid syndrome European Journal of Rheumatology

IF:なし

Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi. SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.

J Diabetes Investig, in press

IF: 3.761

Kuniyuki Aso, Michihito Kono, Michihiro Kono, Toshiyuki Watanabe, Yuka Shimizu, Yusuke Ogata, Yuichiro Fujieda, Masaru Kato, Kenji Oku, Olga Amengual, Shinsuke Yasuda and Tatsuya Atsumi Low complement component 4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus.

Lupus, in press

IF: 2.924

Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Inverse correlation between serum high-molecular-weight adiponectin and proinsulin level in a Japanese

population: the DOSANCO Health Study. J Diabetes Investig, in press

IF: 3.902

Ninagawa K, Fujieda Y, Matsui Y, Kono M, Kamishima T, Iwasaki N, and Atsumi T A case of non-tuberculosis mycobacterium tenosynovitis with rice bodies in a systemic lupus erythematosus patient.
Internal Medicine (IF 1.037)

Fujieda　Y
Diversity of Neuropsychiatric Manifestations in Systemic Lupus Erythematosus Immunological Medicine
(IFなし）

Fujieda Y, Atsumi T.
Antiresorptive Agents-Related Osteonecrosis of the Jaw (ARONJ) in Rheumatoid Arthritis. (letter to the editor) JBMM (IF 2.683)